Oncternal Therapeutics Analyst Ratings
Oncternal Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/07/2023 | 344.37% | Cantor Fitzgerald | → $1.3 | Reiterates | Neutral → Neutral |
| 06/06/2023 | — | HC Wainwright & Co. | Reiterates | → Neutral | |
| 04/04/2023 | — | Maxim Group | Downgrades | Buy → Hold | |
| 04/04/2023 | — | Brookline Capital | Downgrades | Buy → Hold | |
| 04/04/2023 | 344.37% | Cantor Fitzgerald | $4 → $1.3 | Maintains | Overweight |
| 04/04/2023 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 04/04/2023 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 03/22/2023 | 2976.4% | Oppenheimer | $14 → $9 | Maintains | Outperform |
| 03/14/2023 | 2292.75% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 12/22/2022 | 1267.29% | Cantor Fitzgerald | → $4 | Initiates Coverage On | → Overweight |
| 08/10/2022 | 2292.75% | HC Wainwright & Co. | $8 → $7 | Maintains | Buy |
| 05/10/2022 | 1096.38% | Maxim Group | → $3.5 | Initiates Coverage On | → Buy |
| 02/24/2022 | 1609.11% | BTIG | → $5 | Initiates Coverage On | → Buy |
| 04/07/2021 | 4685.51% | Oppenheimer | → $14 | Initiates Coverage On | → Outperform |
| 03/30/2021 | 5369.15% | Brookline Capital | → $16 | Initiates Coverage On | → Buy |
| 03/12/2021 | 2976.4% | HC Wainwright & Co. | $8 → $9 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/07/2023 | 344.37% | 康托·菲茨杰拉德 | →$1.3 | 重申 | 中性→中性 |
| 06/06/2023 | - | HC Wainwright公司 | 重申 | →中性 | |
| 04/04/2023 | - | Maxim集团 | 评级下调 | 购买→Hold | |
| 04/04/2023 | - | 布鲁克林资本 | 评级下调 | 购买→Hold | |
| 04/04/2023 | 344.37% | 康托·菲茨杰拉德 | $4→$1.3 | 维护 | 超重 |
| 04/04/2023 | - | HC Wainwright公司 | 评级下调 | 购买→中性 | |
| 04/04/2023 | - | 奥本海默 | 评级下调 | 超越→表现 | |
| 03/22/2023 | 2976.4% | 奥本海默 | $14→$9 | 维护 | 跑赢大盘 |
| 03/14/2023 | 2292.75% | HC Wainwright公司 | →$7 | 重申 | →购买 |
| 2022年12月22日 | 1267.29% | 康托·菲茨杰拉德 | →$4 | 开始承保 | →超重 |
| 2022年08月10日 | 2292.75% | HC Wainwright公司 | $8→$7 | 维护 | 买 |
| 2022年05月10日 | 1096.38% | Maxim集团 | →$3.5 | 开始承保 | →购买 |
| 02/24/2022 | 1609.11% | BTIG | →$5 | 开始承保 | →购买 |
| 04/07/2021 | 4685.51% | 奥本海默 | →$14 | 开始承保 | →跑赢大盘 |
| 03/30/2021 | 5369.15% | 布鲁克林资本 | →$16 | 开始承保 | →购买 |
| 03/12/2021 | 2976.4% | HC Wainwright公司 | $8→$9 | 维护 | 买 |
What is the target price for Oncternal Therapeutics (ONCT)?
肿瘤治疗公司(ONCT)的目标价格是多少？
The latest price target for Oncternal Therapeutics (NASDAQ: ONCT) was reported by Cantor Fitzgerald on September 7, 2023. The analyst firm set a price target for $1.30 expecting ONCT to rise to within 12 months (a possible 344.37% upside). 10 analyst firms have reported ratings in the last year.
坎托·菲茨杰拉德于2023年9月7日报道了Oncent Treateutics(纳斯达克：onct)的最新目标价。这家分析公司将目标价定为1.3美元，预计ONCT将在12个月内上涨至(可能上涨344.37%)。去年有10家分析公司公布了评级。
What is the most recent analyst rating for Oncternal Therapeutics (ONCT)?
肿瘤治疗公司(ONCT)的最新分析师评级是多少？
The latest analyst rating for Oncternal Therapeutics (NASDAQ: ONCT) was provided by Cantor Fitzgerald, and Oncternal Therapeutics reiterated their neutral rating.
对肿瘤学公司(纳斯达克代码：onct)的最新分析师评级是由坎托·菲茨杰拉德提供的，肿瘤学公司重申了他们的中性评级。
When is the next analyst rating going to be posted or updated for Oncternal Therapeutics (ONCT)?
肿瘤治疗公司(ONCT)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oncternal Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oncternal Therapeutics was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Oncent Treeutics的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Oncent治疗公司的上一次评级是在2023年9月7日提交的，所以你应该预计下一次评级将在2024年9月7日左右的某个时候提供。
Is the Analyst Rating Oncternal Therapeutics (ONCT) correct?
分析师对Onctal Treeutics(ONCT)的评级正确吗？
While ratings are subjective and will change, the latest Oncternal Therapeutics (ONCT) rating was a reiterated with a price target of $0.00 to $1.30. The current price Oncternal Therapeutics (ONCT) is trading at is $0.29, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Onctal Treeutics(ONCT)评级被重申，目标价在0.00美元至1.30美元之间。Onctal Treateutics(ONCT)目前的交易价格为0.29美元，在分析师的预测范围内。